Home › Companies › INOVIO PHARMACEUTICALS INC. › 2024-2025

INOVIO PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and INOVIO PHARMACEUTICALS INC.’s Form 8-K, filed 2025-05-22 (Item 5.07 on EDGAR). Page generated 02 October 2026.

12Reported items
151Asset managers
991Fund votes
2025-05-20Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore INOVIO PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by INOVIO PHARMACEUTICALS INC.

These tallies are INOVIO PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-22 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

INOVIO PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2025-05-20
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Simon X. Benito	7,316,456	--	--	1,747,268	10,956,881	Majority: yes
Elect Director: Roger D. Dansey, M.D.	8,172,640	--	--	891,084	10,956,881	Majority: yes
Elect Director: Ann C. Miller, M.D.	8,360,784	--	--	702,940	10,956,881	Majority: yes
Elect Director: Jacqueline E. Shea, Ph.D.	8,283,381	--	--	780,343	10,956,881	Majority: yes
Elect Director: Jay P. Shepard	8,250,576	--	--	813,148	10,956,881	Majority: yes
Elect Director: David B. Weiner, Ph.D.	8,378,177	--	--	685,547	10,956,881	Majority: yes
Elect Director: Wendy L. Yarno	8,194,523	--	--	869,201	10,956,881	Majority: yes
Elect Director: Lota S. Zoth	8,421,250	--	--	642,474	10,956,881	Majority: yes
Proposal 2: The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025	19,263,636	600,195	156,774	--	0	Majority: yes
Proposal 3: The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement	7,853,003	1,058,436	152,285	--	10,956,881	Majority: yes
Proposal 4: The approval of the amendment and restatement of the Company's 2023 Omnibus Incentive Plan as described in the Proxy Statement	7,764,469	1,165,985	133,270	--	10,956,881	Majority: yes

Source: INOVIO PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-05-22 — read the filing on EDGAR.

How asset managers voted at the INOVIO PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 151 asset managers that disclosed a INOVIO PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of INOVIO PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive officers described in the accompanying proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 7,853,003AGAINST: 1,058,436

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement”): 7,853,003 for, 1,058,436 against, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,674,436 outstanding shares: 21% for, 3% against (24% of the company cast a for/against vote).

The 143 asset managers below cast 99.2% of the shares they voted on this item FOR (6,899,882 for, 53,993 against).

FOR 99.2%

FOR: 6,899,882 (99.2%)AGAINST: 53,993 (0.8%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive offi” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Deep Track Capital, LP	1,676,254	0	For
BlackRock	913,604	0	For
Vanguard	821,322	0	For
Stonepine Capital Management, LLC	701,123	0	For
State Street	485,229	0	For
Fidelity	422,565	0	For
GEODE CAPITAL MANAGEMENT, LLC	366,958	0	For
Northern Trust	293,854	0	For
Charles Schwab	196,988	0	For
Nuveen	103,297	0	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	87,240	0	For
American Century	86,284	0	For
CIBC Private Wealth Group LLC	77,000	0	For
GMT CAPITAL CORP	68,749	0	For
Two Sigma	63,948	0	For
MELLON INVESTMENTS Corp	61,671	0	For
TIAA	47,088	0	For
UBS	43,445	201	For
QUANTITATIVE MASTER SERIES LLC	37,306	0	For
Citadel	28,014	0	For
Dimensional	0	24,469	Against
Equitable	24,231	0	For
Global X	20,757	0	For
Bridge Builder Trust	20,316	0	For
Lincoln Financial	20,100	0	For

Showing the 25 largest of 143 asset managers. See all 143 in the interactive database.

2. TO APPROVE AN AMENDMENT AND RESTATEMENT OF OUR 2023 OMNIBUS INCENTIVE PLAN.

COMPENSATIONMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 7,764,469AGAINST: 1,165,985

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Proposal 4: The approval of the amendment and restatement of the Company's 2023 Omnibus Incentive Plan as described in the Proxy Statement”): 7,764,469 for, 1,165,985 against, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,674,436 outstanding shares: 21% for, 3% against (24% of the company cast a for/against vote).

The 33 asset managers below cast 98% of the shares they voted on this item FOR (2,128,290 for, 43,142 against).

FOR 98%

FOR: 2,128,290 (98.0%)AGAINST: 43,142 (2.0%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT AND RESTATEMENT OF OUR 2023 OMNIBUS INCENTIVE PLAN.” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	783,493	0	For
BlackRock	588,634	0	For
Fidelity	321,735	0	For
Charles Schwab	98,493	0	For
Northern Trust	76,077	0	For
TIAA	46,491	0	For
American Century	0	43,142	Against
QUANTITATIVE MASTER SERIES LLC	37,306	0	For
Equitable	24,231	0	For
Global X	20,757	0	For
Bridge Builder Trust	20,316	0	For
Lincoln Financial	20,100	0	For
AIG/SunAmerica	17,708	0	For
Pacific Life	15,226	0	For
Goldman Sachs	13,215	0	For
State Street	10,677	0	For
ProShares	7,824	0	For
Dimensional	5,726	0	For
Jackson National	4,833	0	For
Nationwide	3,448	0	For
T. Rowe Price	3,030	0	For
Voya	2,698	0	For
Calvert	2,488	0	For
Brinker Capital Destinations Trust	1,121	0	For
PENN SERIES FUNDS INC	900	0	For

Showing the 25 largest of 33 asset managers. See all 33 in the interactive database.

3. To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Ann C. Miller, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 8,360,784WITHHELD: 702,940

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Ann C. Miller, M.D.”): 8,360,784 for, 702,940 withheld, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,674,436 outstanding shares: 23% for, 2% withheld (25% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (2,171,298 for, 0 against).

FOR 100%

FOR: 2,171,298 (100.0%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	783,493	For
BlackRock	588,634	For
Fidelity	321,735	For
Charles Schwab	98,493	For
Northern Trust	76,077	For
TIAA	46,491	For
American Century	43,142	For
QUANTITATIVE MASTER SERIES LLC	37,306	For
Equitable	24,231	For
Global X	20,757	For
Bridge Builder Trust	20,316	For
Lincoln Financial	20,100	For
AIG/SunAmerica	17,708	For
Pacific Life	15,226	For
Goldman Sachs	13,215	For
State Street	10,677	For
ProShares	7,824	For
Dimensional	5,726	For
Jackson National	4,833	For
Nationwide	3,448	For
T. Rowe Price	3,030	For
Voya	2,698	For
Calvert	2,488	For
Brinker Capital Destinations Trust	1,121	For
PENN SERIES FUNDS INC	900	For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

4. To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: David B. Weiner, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 8,378,177WITHHELD: 685,547

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David B. Weiner, Ph.D.”): 8,378,177 for, 685,547 withheld, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,674,436 outstanding shares: 23% for, 2% withheld (25% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (2,171,298 for, 0 against).

FOR 100%

FOR: 2,171,298 (100.0%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	783,493	For
BlackRock	588,634	For
Fidelity	321,735	For
Charles Schwab	98,493	For
Northern Trust	76,077	For
TIAA	46,491	For
American Century	43,142	For
QUANTITATIVE MASTER SERIES LLC	37,306	For
Equitable	24,231	For
Global X	20,757	For
Bridge Builder Trust	20,316	For
Lincoln Financial	20,100	For
AIG/SunAmerica	17,708	For
Pacific Life	15,226	For
Goldman Sachs	13,215	For
State Street	10,677	For
ProShares	7,824	For
Dimensional	5,726	For
Jackson National	4,833	For
Nationwide	3,448	For
T. Rowe Price	3,030	For
Voya	2,698	For
Calvert	2,488	For
Brinker Capital Destinations Trust	1,121	For
PENN SERIES FUNDS INC	900	For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

5. To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Jacqueline E. Shea, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 8,283,381WITHHELD: 780,343

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jacqueline E. Shea, Ph.D.”): 8,283,381 for, 780,343 withheld, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,674,436 outstanding shares: 23% for, 2% withheld (25% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (2,171,298 for, 0 against).

FOR 100%

FOR: 2,171,298 (100.0%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	783,493	For
BlackRock	588,634	For
Fidelity	321,735	For
Charles Schwab	98,493	For
Northern Trust	76,077	For
TIAA	46,491	For
American Century	43,142	For
QUANTITATIVE MASTER SERIES LLC	37,306	For
Equitable	24,231	For
Global X	20,757	For
Bridge Builder Trust	20,316	For
Lincoln Financial	20,100	For
AIG/SunAmerica	17,708	For
Pacific Life	15,226	For
Goldman Sachs	13,215	For
State Street	10,677	For
ProShares	7,824	For
Dimensional	5,726	For
Jackson National	4,833	For
Nationwide	3,448	For
T. Rowe Price	3,030	For
Voya	2,698	For
Calvert	2,488	For
Brinker Capital Destinations Trust	1,121	For
PENN SERIES FUNDS INC	900	For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

6. To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Jay P. Shepard

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 8,250,576WITHHELD: 813,148

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jay P. Shepard”): 8,250,576 for, 813,148 withheld, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,674,436 outstanding shares: 22% for, 2% withheld (25% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (2,168,810 for, 0 against).

FOR 99.8%

FOR: 2,168,810 (99.9%)ABSTAIN: 2,488 (0.1%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	783,493	0	For
BlackRock	588,634	0	For
Fidelity	321,735	0	For
Charles Schwab	98,493	0	For
Northern Trust	76,077	0	For
TIAA	46,491	0	For
American Century	43,142	0	For
QUANTITATIVE MASTER SERIES LLC	37,306	0	For
Equitable	24,231	0	For
Global X	20,757	0	For
Bridge Builder Trust	20,316	0	For
Lincoln Financial	20,100	0	For
AIG/SunAmerica	17,708	0	For
Pacific Life	15,226	0	For
Goldman Sachs	13,215	0	For
State Street	10,677	0	For
ProShares	7,824	0	For
Dimensional	5,726	0	For
Jackson National	4,833	0	For
Nationwide	3,448	0	For
T. Rowe Price	3,030	0	For
Voya	2,698	0	For
Calvert	0	2,488	Abstain
Brinker Capital Destinations Trust	1,121	0	For
PENN SERIES FUNDS INC	900	0	For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

7. To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Lota S. Zoth

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%

FOR: 8,421,250WITHHELD: 642,474

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Lota S. Zoth”): 8,421,250 for, 642,474 withheld, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,674,436 outstanding shares: 23% for, 2% withheld (25% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (2,160,739 for, 0 against).

FOR 99.5%

FOR: 2,160,739 (99.5%)ABSTAIN: 10,559 (0.5%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	783,493	0	For
BlackRock	588,634	0	For
Fidelity	321,735	0	For
Charles Schwab	98,493	0	For
Northern Trust	76,077	0	For
TIAA	46,491	0	For
American Century	43,142	0	For
QUANTITATIVE MASTER SERIES LLC	37,306	0	For
Equitable	24,231	0	For
Global X	20,757	0	For
Bridge Builder Trust	20,316	0	For
Lincoln Financial	20,100	0	For
AIG/SunAmerica	17,708	0	For
Pacific Life	15,226	0	For
Goldman Sachs	13,215	0	For
State Street	10,677	0	For
ProShares	7,824	0	For
Dimensional	0	5,726	Abstain
Jackson National	0	4,833	Abstain
Nationwide	3,448	0	For
T. Rowe Price	3,030	0	For
Voya	2,698	0	For
Calvert	2,488	0	For
Brinker Capital Destinations Trust	1,121	0	For
PENN SERIES FUNDS INC	900	0	For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

8. To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Roger D. Dansey, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 8,172,640WITHHELD: 891,084

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Roger D. Dansey, M.D.”): 8,172,640 for, 891,084 withheld, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,674,436 outstanding shares: 22% for, 2% withheld (25% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (2,168,661 for, 0 against).

FOR 99.8%

FOR: 2,168,661 (99.9%)ABSTAIN: 2,637 (0.1%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	783,493	0	For
BlackRock	588,634	0	For
Fidelity	321,735	0	For
Charles Schwab	98,493	0	For
Northern Trust	76,077	0	For
TIAA	46,491	0	For
American Century	43,142	0	For
QUANTITATIVE MASTER SERIES LLC	37,306	0	For
Equitable	24,231	0	For
Global X	20,757	0	For
Bridge Builder Trust	20,316	0	For
Lincoln Financial	20,100	0	For
AIG/SunAmerica	17,708	0	For
Pacific Life	15,226	0	For
Goldman Sachs	13,215	0	For
State Street	10,677	0	For
ProShares	7,824	0	For
Dimensional	5,726	0	For
Jackson National	4,833	0	For
Nationwide	3,448	0	For
T. Rowe Price	3,030	0	For
Voya	2,698	0	For
Calvert	0	2,488	Abstain
Brinker Capital Destinations Trust	1,121	0	For
PENN SERIES FUNDS INC	900	0	For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

9. To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Simon X. Benito

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD 19%

FOR: 7,316,456WITHHELD: 1,747,268

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Simon X. Benito”): 7,316,456 for, 1,747,268 withheld, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,674,436 outstanding shares: 20% for, 5% withheld (25% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (2,046,529 for, 0 against).

FOR 94%

FOR: 2,046,529 (94.3%)ABSTAIN: 124,769 (5.7%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	783,493	0	For
BlackRock	588,634	0	For
Fidelity	321,735	0	For
Charles Schwab	98,493	0	For
Northern Trust	0	76,077	Abstain
TIAA	46,491	0	For
American Century	43,142	0	For
QUANTITATIVE MASTER SERIES LLC	37,306	0	For
Equitable	24,231	0	For
Global X	20,757	0	For
Bridge Builder Trust	20,316	0	For
Lincoln Financial	0	20,100	Abstain
AIG/SunAmerica	17,708	0	For
Pacific Life	15,226	0	For
Goldman Sachs	13,215	0	For
State Street	0	10,677	Abstain
ProShares	7,824	0	For
Dimensional	0	5,726	Abstain
Jackson National	0	4,833	Abstain
Nationwide	3,448	0	For
T. Rowe Price	3,030	0	For
Voya	0	2,698	Abstain
Calvert	0	2,488	Abstain
Brinker Capital Destinations Trust	0	1,121	Abstain
PENN SERIES FUNDS INC	0	900	Abstain

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

10. To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Wendy L. Yarno

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 8,194,523WITHHELD: 869,201

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Wendy L. Yarno”): 8,194,523 for, 869,201 withheld, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,674,436 outstanding shares: 22% for, 2% withheld (25% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (2,158,251 for, 0 against).

FOR 99.3%

FOR: 2,158,251 (99.4%)ABSTAIN: 13,047 (0.6%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	783,493	0	For
BlackRock	588,634	0	For
Fidelity	321,735	0	For
Charles Schwab	98,493	0	For
Northern Trust	76,077	0	For
TIAA	46,491	0	For
American Century	43,142	0	For
QUANTITATIVE MASTER SERIES LLC	37,306	0	For
Equitable	24,231	0	For
Global X	20,757	0	For
Bridge Builder Trust	20,316	0	For
Lincoln Financial	20,100	0	For
AIG/SunAmerica	17,708	0	For
Pacific Life	15,226	0	For
Goldman Sachs	13,215	0	For
State Street	10,677	0	For
ProShares	7,824	0	For
Dimensional	0	5,726	Abstain
Jackson National	0	4,833	Abstain
Nationwide	3,448	0	For
T. Rowe Price	3,030	0	For
Voya	2,698	0	For
Calvert	0	2,488	Abstain
Brinker Capital Destinations Trust	1,121	0	For
PENN SERIES FUNDS INC	900	0	For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

11. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

97% Majority: yes · of votes cast

FOR 97%

FOR: 19,263,636AGAINST: 600,195

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31,”): 19,263,636 for, 600,195 against, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,674,436 outstanding shares: 52.5% for, 2% against (54.2% of the company cast a for/against vote).

The 30 asset managers below cast 99.9% of the shares they voted on this item FOR (2,171,149 for, 149 against).

FOR 99.9%

FOR: 2,171,149 (100.0%)AGAINST: 149 (0.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	783,493	For
BlackRock	588,634	For
Fidelity	321,735	For
Charles Schwab	98,493	For
Northern Trust	76,077	For
TIAA	46,491	For
American Century	43,142	For
QUANTITATIVE MASTER SERIES LLC	37,306	For
Equitable	24,231	For
Global X	20,757	For
Bridge Builder Trust	20,316	For
Lincoln Financial	20,100	For
AIG/SunAmerica	17,708	For
Pacific Life	15,226	For
Goldman Sachs	13,215	For
State Street	10,677	For
ProShares	7,824	For
Dimensional	5,726	For
Jackson National	4,833	For
Nationwide	3,448	For
T. Rowe Price	3,030	For
Voya	2,698	For
Calvert	2,488	For
Brinker Capital Destinations Trust	1,121	For
PENN SERIES FUNDS INC	900	For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

12. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (17,069 for, 0 against).

FOR: 17,069 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
JPMorgan	16,973	For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	50	For
TD Waterhouse Canada Inc.	46	For

Largest INOVIO PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked by the number of INOVIO PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 36,674,436 shares outstanding at the time of that meeting.

Top INOVIO PHARMACEUTICALS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Deep Track Capital, LP	4.57%
2	BlackRock	2.49%
3	Vanguard	2.24%
4	Stonepine Capital Management, LLC	1.91%
5	State Street	1.32%
6	Fidelity	1.15%
7	GEODE CAPITAL MANAGEMENT, LLC	1.00%
8	Northern Trust	0.80%
9	Charles Schwab	0.54%
10	Nuveen	0.28%

Reported INOVIO PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

INOVIO PHARMACEUTICALS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
JANUS HENDERSON GROUP PLC	18.18%	13G
HIGHBRIDGE CAPITAL MANAGEMENT LLC	16.88%	13G
Adage Capital Management, L.P.	11.54%	13G
Alyeska Investment Group, L.P.	10.91%	13G
Highbridge Capital Management, LLC	9.91%	13G
BlackRock	6.32%	13F
Vanguard Group	5.53%	13F
Stonepine Capital Management, LLC	3.91%	13G
Geode Capital	2.31%	13F
State Street	1.40%	13F

Percentages above are of 36,674,436 shares outstanding, as reported by INOVIO PHARMACEUTICALS INC. on its Form 10-Q dated 2025-05-09 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from INOVIO PHARMACEUTICALS INC.’s 10-Q dated 2025-05-09. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At INOVIO PHARMACEUTICALS INC.'s shareholder meeting held 2025-05-20, in the 2024-2025 proxy season, 151 asset managers reported how they voted in their SEC Form N-PX filings, covering 991 separate fund positions. Their filings are grouped here into 12 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the resolution regarding compensation of our named… — FOR was 88% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: INOVIO PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-22.

INOVIO PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.